Literature DB >> 3528089

Misonidazole and other hypoxia markers: metabolism and applications.

A J Franko.   

Abstract

A substantial effort is being devoted to developing markers for hypoxia in tumors. Most of the work to date has been performed on misonidazole (MISO), which is selectively metabolized by hypoxic cells to reactive products that bind covalently to cellular constituents. This paper attempts to review the metabolism of MISO as it relates to binding, to summarize several of the properties of the binding of MISO to cells and tissues which appear to be directly relevant to the characteristics of the reactive species involved, and to evaluate the potential of MISO and other nitroheterocycles as markers for hypoxia. Four roles for a hypoxic marker are considered. MISO labeled with 3H or 14C is a good marker for local radiobiological hypoxia in autoradiograms of tumor sections, but more work is required to investigate factors other than oxygen concentration that conceivably might affect the binding process. In quantitating hypoxic fraction in tumors using non-destructive techniques, which has been modelled by correlating surviving fraction with 14C-misonidazole uptake, non-specific binding to aerobic and necrotic tissue limits the accuracy of the estimate, but useful clinical applications can still be envisaged. For quantitation of a change in the hypoxic fraction of an individual tumor using serial assays, preliminary data suggest that MISO binding should be a sensitive assay. Fluorescent nitroheterocycles have a great deal of potential as markers to enable the sorting of tumor cell suspensions into portions derived from the hypoxic and aerobic regions, but better compounds are needed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528089     DOI: 10.1016/0360-3016(86)90257-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  HL-91-technetium-99m: a new marker of viability in ischemic myocardium.

Authors:  R D Okada; G Johnson; K N Nguyen; L R Carlson; D Beju
Journal:  J Nucl Cardiol       Date:  1999 May-Jun       Impact factor: 5.952

Review 2.  Cardiac metabolism: a technical spectrum of modalities including positron emission tomography, single-photon emission computed tomography, and magnetic resonance spectroscopy.

Authors:  R Valkema; B L van Eck-Smit; E E van der Wall
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

Review 3.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 4.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

5.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Combination of etanidazole with cyclophosphamide and platinum complexes.

Authors:  B A Teicher; T S Herman; L Shulman; G Bubley; C N Coleman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Hydroethidine: a fluorescent redox probe for locating hypoxic cells in spheroids and murine tumours.

Authors:  P L Olive
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

Authors:  J M Cline; D E Thrall; R L Page; A J Franko; J A Raleigh
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

9.  Reducing the hypoxic fraction of a tumour model by growth in low glucose.

Authors:  L Hlatky; R K Sachs; C S Ring
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

10.  Microscopic distribution of misonidazole in mouse tissues.

Authors:  L M Cobb; J Nolan; P O'Neill
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.